MedTrace Logo

Heparin Antibodies in Intensive Care Unit Patients (HAICU)

NCT00283322 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2007-12-06

No results posted yet for this study

Summary

Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous thromboembolism leads to significant morbidity and can be fatal. Unfractionated heparin and low molecular weight heparin are commonly used to prevent venous thromboembolism. Heparin induced thrombocytopenia, an untoward consequence of exposure to heparin, is an immune disorder that may develop in patients treated with heparin products. Determining the prevalence of heparin induced thrombocytopenia and its relationship to preventive and therapeutic heparin and low molecular weight heparin will help clinicians more appropriately choose methods of venous thromboembolism prophylaxis and treatment in the critically ill, ICU population.

The objective of this study is to determine the prevalence of heparin-induced antibodies on admission to the ICU and the development of new heparin-antibodies during the first week of hospitalization.

Conditions

  • Heparin-Induced Thrombocytopenia

Interventions

OTHER

blood samples (2)

Two blood samples were obtained from patients and tested for heparin antibodies.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Robert L Levine, MD · The University of Texas, Houston

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283322 on ClinicalTrials.gov